Pelthos Therapeutics Signs Major Pharmacy Benefit Manager Agreement Expanding Patient Access to ZELSUVMI™ (berdazimer) Topical Gel, 10.3%

ZELSUVMI is the first and only FDA-approved at-home treatment for molluscum contagiosum, a
highly contagious viral skin condition affecting an estimated 16.7 million people, with up to
6 million new incidents reported every year in the United States

Read more at globenewswire.com